Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesylate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesilate monohydrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesilate monohydrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesylate -

Canadá - inglês - Health Canada

sanofi-aventis canada inc - dolasetron mesylate - solution - 20mg - dolasetron mesylate 20mg - 5-ht3 receptor antagonists

Canadá - inglês - Health Canada

sanofi-aventis canada inc - dolasetron mesylate - tablet - 50mg - dolasetron mesylate 50mg - 5-ht3 receptor antagonists

Canadá - inglês - Health Canada

sanofi-aventis canada inc - dolasetron mesylate - tablet - 100mg - dolasetron mesylate 100mg - 5-ht3 receptor antagonists

Estados Unidos - inglês - NLM (National Library of Medicine)

validus pharmaceuticals llc - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 50 mg - anzemet tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. anzemet tablets are contraindicated in patients known to have hypersensitivity to the drug.

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - dolasetron mesylate - tablets - 50 milligram

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - dolasetron mesylate - tablets - 200 milligram